Asset Details
Do you wish to reserve the book?
GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4
Do you wish to request the book?
GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
GTPgammaS incorporation in the rat brain: a study on mu-opioid receptors and CXCR4
2008
Overview
Chemokine and opioid receptors are G-protein-coupled receptors that play important roles in both the central nervous system and the immune system. The long-term goal of our research is to establish whether opioids regulate the activity of the chemokine receptor CXCR4 (one of the major HIV co-receptors) in the brain. In this research, we studied the anatomical distribution of functional receptors in young and adult animals by using the [(35)S]GTPgammaS \"binding\" assay as an indication of G-protein activation by CXCL12 (the natural CXCR4 ligand) or by mu-opioid agonists. Brain slices or homogenates from Holtzmann rats of different ages (from 2 to 21 days old and adult animals) were treated with CXCL12 (0.001-100 nM), D: -ala2,MePhe4,gly-ol5]enkephalin (DAMGO; 0.0003-10 microM) or morphine (0.0003-10 microM) and then processed for the assay. Our results show stimulation of both mu-OR and CXCR4 in several brain areas, including cortex and hippocampus (p < 0.001); this effect is dose and age dependent, and the magnitude of response varies among different brain regions. Furthermore, AMD3100 (100 ng/ml), a specific CXCR4 antagonist, abolished CXCL12 stimulation in all the brain regions analyzed (p < 0.001). Our findings suggest a similar pattern of expression for mu-OR and CXCR4 in the brain, supporting the possibility of an interaction between the two G-protein-coupled receptors in vivo. This might be relevant to the role of opiates in HIV neuropathogenesis.
Subject
/ Analgesics, Opioid - pharmacology
/ Animals
/ Chemokine CXCL12 - pharmacology
/ Enkephalin, Ala-MePhe-Gly- - pharmacology
/ Female
/ Guanosine 5'-O-(3-Thiotriphosphate) - metabolism
/ Narcotic Antagonists - pharmacology
/ Neurotransmitter Agents - pharmacology
/ Rats
/ Receptors, CXCR4 - biosynthesis
/ Receptors, CXCR4 - drug effects
/ Receptors, Opioid, mu - antagonists & inhibitors
